Reneo cuts 70% of staff following Phase III trial failure
Reneo’s mavodelpar failed to meet its endpoints in the Phase III trial in primary mitochondrial myopathies, a rare genetic disorder.
Reneo’s mavodelpar failed to meet its endpoints in the Phase III trial in primary mitochondrial myopathies, a rare genetic disorder.
What's Your Reaction?
